PubMed · 7554593
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
D S Mastrogiannis, R A Knuppel. 1995. Labor induced using methods that do not involve oxytocin.. https://doi.org/10.1097/00003081-199506000-00008
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
INTRODUCTION: Vaginal application of prostaglandins is well known and accepted for induction of labor. In this study we compared 50 microg misoprostol to 25 microg misoprostol and 3 mg Minprostin, applied as a single dose every 24 hours. MATERIALS AND METHODS: Three periods in which three different prostaglandin preparations were given to induce labor were retrospectively evaluated. RESULTS: The median time from induction to delivery showed 50 microg misoprostol (25 hours) to be more potent than 25 microg (38 hours) and Minprostin (35 hours). As a consequence, hyperstimulation was more frequent (10% vs. 4% & 1%), as well as caesarean section on the indication of foetus mortuus imminens. The advantages were fewer caesarean sections on the indication of dystocia and therefore no difference in the overall section rate. The oxytocin augmentation rate was also less frequent, as were the instrumental delivery rate, anal sphincter disruptions and postpartum hemorrhage. CONCLUSION: This study indicates that one must choose between a potent treatment, which implies a 10% risk of uterine hyperstimulation, and a less potent treatment with an enhanced risk of instrumental delivery and disruption of the anal sphincter.
Nitric oxide (NO) synthesized by fetal membranes may act either directly inhibiting myometrium contractility or indirectly interacting with tocolytic agents as prostaglandins (PGs). Here we examined if NO could modulate prostaglandin E(2) 9-ketoreductase (9-KPR) activity in human fetal membranes (HFM). 9-KPR is the enzyme that converts PGE(2) into PGF(2alpha), the main PGs known to induce uterine contractility at term. Chorioamnion explants obtained from elective caesareans were incubated with aminoguanidine (AG), an iNOS inhibitor, or NOC-18, a NO donor. NOC-18 (2mM) increased PGE(2) production and diminished PGF(2alpha) synthesis in HFM. AG presented the opposite effect. When we evaluated the activity of 9-KPR by the conversion of [(3)H]-PGE(2) into [(3)H]-PGF(2alpha) and 13,14-dihidro-15-keto prostaglandin F(2alpha) (the PGF(2alpha) metabolite), we found that NOC-18 inhibited 9-KPR activity. Interestingly, AG did not elicit any effect on 9-KPR but l-NAME, a non-selective NOS inhibitor, significantly increased its activity. Our data suggests that exogenous NO inhibits 9-KPR activity in HFM, thus modulating the synthesis of important labor mediators as PGF(2alpha).
Microvascular dysfunction and increased oxidative stress are major hallmarks of the systemic sclerosis disease process. The primary objective of this study was to test whether there is a link between peak postocclusive hyperemia and urinary levels of the F2-isoprostane 15-F2t-IsoP (8-iso-PGF2alpha) in patients suffering from systemic sclerosis. We enrolled 43 patients suffering from systemic sclerosis, 33 patients with primary Raynaud's phenomenon (RP), and 25 healthy volunteers. Microvascular function was assessed using the postocclusive hyperemia monitored by laser Doppler flowmetry. Endothelium-independent response was monitored after 0.4 mg sublingual nitroglycerin. Oxidative stress status was assessed by urinary levels of the F2-isoprostane 15-F2t-IsoP using GC-MS. The peak postocclusive vascular conductance was altered in subjects with systemic sclerosis and primary RP compared to controls (respectively 28 (7-48), 30 (13-48), and 39.9 (13-63) mV/mm Hg, p = 0.01). F2-isoprostanes were increased in the systemic sclerosis group compared to primary Raynaud's phenomenon and healthy controls (respectively 230 (155-387), 182 (101-284), and 207 (109-291) pg/mg, p = 0.006). In patients suffering from systemic sclerosis, there was a significant inverse correlation between F2-isoprostanes and postocclusive hyperemia, expressed as raw data (R = -0.45, p = 0.007) or as an increase over baseline (R = -0.28, p = 0.04). Conversely, no correlation was found with the nitroglycerin response. In conclusion, we provide evidence that there is an inverse correlation between postocclusive hyperemia and urinary F2-isoprostane levels in patients suffering from systemic sclerosis. Whether oxygen free radicals initiate the vascular dysfunction or whether there is an initial trigger that initiates both processes will need to be further clarified in future studies.